SPY384.24+0.35 0.09%
DIA311.87+0.10 0.03%
IXIC13,530.92+73.67 0.55%

Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases; AbbVie To Pay Morphic License Fee Of $20 Million, With Future Potential Milestones And Royalties

Benzinga · 08/25/2020 10:33